FDC launches 2 variants of Favipiravir in India at Rs 55 per tablet

Drug firm FDC Ltd on Tuesday said it has launched two variants of the COVID-19 drug Favipiravir under the brand names PiFLU and Favenza. The Drug Controller General of India (DCGI) had earlier approved the use of Favipiravir, an off-patent, oral antiviral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms, FDC said in a statement.




Read the Rest at INDIA TV

Leave a Reply

Your email address will not be published. Required fields are marked *